NCT05857644View on ClinicalTrials.gov

A Study to Compare How the Study Medicine (PF-07923568) is Processed in Participants With Different Levels of Loss of Liver Function to Healthy Participants.

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

June 7, 2023

Primary Completion Date

February 7, 2024

Study Completion Date

February 7, 2024

Conditions
Liver DiseasesHepatic Impairment
Interventions
DRUG

PF-07923568

One time dose of 4 capsules taken orally.

Trial Locations (3)

32809

Orlando Clinical Research Center, Orlando

33603

Genesis Clinical Research, LLC, Tampa

92780

Orange County Research Center, Tustin

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05857644 - A Study to Compare How the Study Medicine (PF-07923568) is Processed in Participants With Different Levels of Loss of Liver Function to Healthy Participants. | Biotech Hunter | Biotech Hunter